

**Associate Directors Monthly Meeting
MINUTES**

MEETING DATE/TIME	Monday, July 8, 2019 / 1 – 2 pm			
EXECUTIVE OWNER	Eileen White			
EXECUTIVE NOTE TAKER	Allison Warzala			
ATTENDEES		Present		Present
	David August		Edmund Lattime	X(phone)
	Andrew Evens	X	Gina Londino-Greenberg	X
	Shridar Ganesan		Sharon Manne	X
	Howard Hochster		Linda Tanzer	X(phone)
	Yibin Kang	X(phone)	Allison Warzala	
	Anita Kinney	X(phone)	Eileen White	X
INVITED GUESTS	Paul Novembre, Willetta Boswell			

AGENDA TOPICS		
TOPIC	DISCUSSION/CONCLUSION	RECOMMENDATION/ ACTION
Urgent issues	<ol style="list-style-type: none"> Setting the 2020 EAB agenda, so that Paul knows who to invite and who is essential to attend. 	<ol style="list-style-type: none"> Paul will speak with Steve Libutti. Everyone should attend the EAB.
EAB Debrief	<ol style="list-style-type: none"> The melanoma connection to the CPC program is important. CPC could engage more obesity-related research through work by Qin and Bandera, and Manne's new recruit. Though alcohol use is a co-carcinogen with tobacco, it is not a major issue in NJ. No CPC members doing alcohol-related research have cancer-relevant funding. There is no CCSG requirement that consortium partners need to demonstrate increased cancer-relevant work. There continues to be confusion over the roles of the Clinical Research and Translational Research ADs. Due to the growing immunoncology focus within the CMG program, it is advised that the CMG program be renamed "Tumor Microenvironment" program. The Flow Cytometry core and Immune Monitoring core need to remain separate shared resources, so that the Princeton Flow Cytometry site can remain and the Immune Monitoring core can pay for Flow Cytometry services. The DSGs need to be more involved with clinical trials. CIPT needs to do more work related to BRCA. Clinical Research does not seem to have as much structure as Basic Research for faculty development. 	<ol style="list-style-type: none"> Elliot Coups' symptom management project might be able to be revised for collaboration with CIPT (Mehnert). Jian Cao and Adam Berger could be additional potential partners. Investigate the possibility of a P20/SPORE on obesity in African-Americans. The researchers with Rutgers Center for Alcohol Studies will be investigated for potential collaborators. There will be no need to establish metrics to measure whether Princeton University is increasing its cancer-relevant work due to its consortium partner status. The organizational chart may again need to be revised. As the developing Immunoncology program becomes ready to become its own program, the CMG program will be renamed to "Tumor Microenvironment" program and then transition back to CMG program after the Immunoncology program is established. The Flow Cytometry and Immune Monitoring Cores will share space, but remain separate shared resource. Need to identify clinicians throughout the health system whose skills and abilities can be leveraged. They should be given protected time for research. Selection of these individuals should be careful. There needs to be greater infrastructure in the hospital system to support this cultivation. Drs. Lattime, August, and Evens will discuss further how to build this structure for Clinical faculty development.

Next Meeting: Monday, August 12, 2019, 1 – 2 pm		